百时美施贵宝（Bristol Myers Squibb）发布了2025年关键的非通用会计准则（Non-GAAP）项目的指南假设。公司预计2025年总收入约为455亿美元，比市场共识的478.45亿美元低。收入受益于增长产品组合的持续强劲表现，但因Revlimid、Pomalyst、Sprycel和Abraxane等药物的仿制药冲击，核心产品组合预计收入将下降约18%至20%，此外约5亿美元的外汇影响也对收入有负面作用。调整后的每股收益范围预计为6.55美元至6.85美元。
以上内容来自Benzinga Earnings专栏，原文如下：
Financial Guidance Bristol Myers Squibb is providing key 2025 non-GAAP line-item guidance assumptions as outlined below. We estimate total revenues to be approximately $45.5 billion, reflecting, as previously expected, the near-term impact of generics across Revlimid, Pomalyst, Sprycel and Abraxane, which we expect to result in a revenue decline of approximately 18-20% of the Legacy Portfolio. This is expected to be partially offset by the continued strength of our Growth Portfolio. This guidance also reflects an approximate $500 million expected negative impact to revenue due to foreign exchange.
| 2025 Non-GAAP1 Line-Item Guidance | |
| Total Revenues (Reported & Ex-F/X) | ~$45.5 billion |
| Gross Margin % | ~72% |
| Operating Expenses2 | ~$16 billion |
| Other Income/(Expense) | ~$30 million |
| Tax Rate | ~18% |
| Diluted EPS | $6.55-$6.85 |
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。